Patents by Inventor Yanran Ai

Yanran Ai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240317744
    Abstract: The present application provides bicyclic urea compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: March 12, 2024
    Publication date: September 26, 2024
    Inventors: Xin Li, Oleg Vechorkin, Yanran Ai, Onur Atasoylu, Hang Thi Dang, Brent Douty, Chunhong He, Peng He, Michael Liang, Minh Nguyen, Evan Styduhar, Anlai Wang, Xiaozhao Wang, Hai Fen Ye, Eddy W. Yue, Ke Zhang, Peng Zhao
  • Publication number: 20240300948
    Abstract: The present application provides heterocyclic compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: February 22, 2024
    Publication date: September 12, 2024
    Inventors: Charles Cole, Yanran Ai, Eddy W. Yue
  • Patent number: 12084430
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: September 10, 2024
    Assignee: Incyte Corporation
    Inventors: Cooper Taylor, Yanran Ai, Chunhong He, Ke Zhang, Eddy W. Yue
  • Patent number: 12006320
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: June 11, 2024
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart
  • Publication number: 20240150354
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: August 24, 2023
    Publication date: May 9, 2024
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Patent number: 11780840
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: October 10, 2023
    Assignee: Incyte Corporation
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Publication number: 20230295124
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: March 16, 2023
    Publication date: September 21, 2023
    Inventors: Cooper Taylor, Yanran Ai, Chunhong He, Ke Zhang, Zhitong Zheng, Eddy W. Yue
  • Publication number: 20230128195
    Abstract: The present invention provides methods for the synthesis of ketones involving a Ni/Zr-mediated coupling reaction. The Ni/Zr-mediated ketolization reactions can be used in the synthesis of halichondrins (e.g., halichondrin A, B, C; homohalichondrin A, B, C; norhalichondrin A, B, C), and analogs thereof. Therefore, the present invention also provides synthetic methods useful for the synthesis of halichondrins, and analogs thereof. Also provided herein are compounds (i.e., intermediates) useful in the synthesis of halichondrins, and analogs thereof.
    Type: Application
    Filed: November 23, 2022
    Publication date: April 27, 2023
    Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Yanran Ai, Ning Ye, Qiaoyi Wang, Kenzo Yahata, Kentaro Iso, Santhosh Reddy Naini, Shuji Yamashita, Jihoon Lee, Isao Ohashi, Takashi Fukuyama
  • Patent number: 11548898
    Abstract: The present invention provides methods for the synthesis of ketones involving a Ni/Zr-mediated coupling reaction. The Ni/Zr-mediated ketolization reactions can be used in the synthesis of halichondrins (e.g., halichondrin A, B, C; homohalichondrin A, B, C; norhalichondrin A, B, C), and analogs thereof. Therefore, the present invention also provides synthetic methods useful for the synthesis of halichondrins, and analogs thereof. Also provided herein are compounds (i.e., intermediates) useful in the synthesis of halichondrins, and analogs thereof. In particular, the present invention provides methods and compounds useful in the synthesis of compound of Formula (H3-A).
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: January 10, 2023
    Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Yanran Ai, Ning Ye, Qiaoyi Wang, Kenzo Yahata, Kentaro Iso, Santhosh Reddy Naini, Shuji Yamashita, Jihoon Lee, Isao Ohashi, Takashi Fukuyama
  • Publication number: 20220411383
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: May 24, 2021
    Publication date: December 29, 2022
    Inventors: Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue, Andrew W. Buesking
  • Publication number: 20220169649
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: July 1, 2021
    Publication date: June 2, 2022
    Inventors: Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Publication number: 20210395258
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: June 24, 2021
    Publication date: December 23, 2021
    Inventors: Stacey Shepard, Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart
  • Patent number: 11161838
    Abstract: This application relates to compounds of the following Formula: or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: November 2, 2021
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Yanran Ai, Andrew P. Combs, Artem Shvartsbart
  • Patent number: 11078204
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: August 3, 2021
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart
  • Publication number: 20210230177
    Abstract: The present invention provides methods for the synthesis of ketones involving a Ni/Zr-mediated coupling reaction. The Ni/Zr-mediated ketolization reactions can be used in the synthesis of halichondrins (e.g., halichondrin A, B, C; homohalichondrin A, B, C; norhalichondrin A, B, C), and analogs thereof. Therefore, the present invention also provides synthetic methods useful for the synthesis of halichondrins, and analogs thereof. Also provided herein are compounds (i.e., intermediates) useful in the synthesis of halichondrins, and analogs thereof.
    Type: Application
    Filed: July 6, 2018
    Publication date: July 29, 2021
    Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Yanran Ai, Ning Ye, Qiaoyi Wang, Kenzo Yahata, Kentaro Iso, Santhosh Reddy Naini, Shuji Yamashita, Jihoon Lee, Isao Ohashi, Takashi Fukuyama
  • Patent number: 11046658
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: June 29, 2021
    Assignee: Incyte Corporation
    Inventors: Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue, Andrew W. Buesking
  • Publication number: 20200148689
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: November 12, 2019
    Publication date: May 14, 2020
    Inventors: Stacey Shepard, Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart
  • Publication number: 20200148671
    Abstract: This application relates to compounds of the following Formula: or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: November 12, 2019
    Publication date: May 14, 2020
    Inventors: Stacey Shepard, Yanran Ai, Andrew P. Combs, Artem Shvartsbart
  • Publication number: 20200002295
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: July 1, 2019
    Publication date: January 2, 2020
    Inventors: Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue